10/20/2010

ThermoGenesis has entered a licensing deal that will give BioParadox exclusive global rights to its Res-Q stem cell processing device for the production of platelet-rich plasma using peripheral blood. ThermoGenesis has filed for FDA market clearance for this specific use of the device.

Related Summaries